In the future, it is promising to develop more precise tools to predict the anti-PD-1/PD-L1 therapeutic efficacy in esophageal cancer patients by standardizing and normalizing diverse biomarkers, intensively investigating the relations of different biomarkers, and applying computer technologies and medical databases, which is of great significance for individualized immunotherapy. The gene discussed is PDCD1; the disease is esophageal cancer.